$PTC

PTC Inc (PTC) shares rose 4.5% to $136.65. GuruFocus values PTC at $216.73, a 36.9% discount. PTC has a GF Score of 86/100, strong in profitability and growth, but weak in valuation and momentum. Insiders sold $11.5M in shares over the past year. P/E ratio is 13.2x, below its 5-year median of 46.2x.

Shares of enterprise software and SaaS companies, including Procore Technologies (PCOR), Bentley Systems (BSY), PTC (PTC), Samsara (IOT), and Agilysys (AGYS), rose as investors shifted capital from semiconductor and AI-hardware stocks following calls for a slowdown in AI development. Samsara reported strong Q2 2026 results and raised its full-year revenue guidance, leading to analyst upgrades and higher price targets. The company's shares are up 23.2% year-to-date.

PTC Inc. launched Jetstream and Orbit to enhance collaboration and lifecycle management. The company is integrating AI across workflows and introducing new pricing models for advanced features. Growth is driven by competitive wins and Codebeamer expansion, according to a Citi conference transcript.

Sangamo Therapeutics (SGMOQ) sold its Fabry disease gene therapy program to PTC Therapeutics for $111M upfront, with up to $100M in milestones. The deal is part of Sangamo's Chapter 11 restructuring, with a bankruptcy court hearing scheduled for September 10, 2026. The transaction is subject to court approval and regulatory milestones.

Shares of Braze, Procore, PTC, Samsara, and Zeta Global rose after strong earnings reports and positive AI-driven growth commentary from major tech firms. Salesforce, CrowdStrike, and Okta showed AI boosted product adoption and revenue. Braze's stock surged 10%, trading near its 52-week high.

PTC Therapeutics will acquire ST-920, a gene therapy for Fabry disease, from Sangamo Therapeutics for $111M upfront and up to $100M in milestones. PTC plans to seek FDA accelerated approval in 2023, with a potential 2027 launch. The therapy showed kidney function improvements in clinical trials.

PTC Therapeutics presented new data on Sephience (sepiapterin) at the 2026 SSIEM Symposium, showing sustained metabolic control, diet liberalization, and a favorable safety profile in PKU patients. Key findings include a 100% greater reduction in blood Phe for participants on sapropterin and clinically meaningful reductions in high baseline Phe levels. Sephience is approved in the U.S., EU, Japan, and other countries for PKU treatment.

Oracle, NetScaler, GitLab, Microsoft, and SAP released critical security patches to address vulnerabilities. GitLab and SAP flaws are being actively exploited. Cl0p claims to have stolen data from Shell via a PTC flaw. Infostealers and mobile fraud threats emerged, including MacSync Stealer and Android NFC fraud. LiteLLM compromise exposed credentials. AI-assisted attacks targeted cryptocurrency users and Taiwan government systems, with AI agents showing destructive behavior.

Barclays analyst Saket Kalia kept a 'Buy' rating and $155 price target on PTC. The average target is $172.90, implying 16.4% upside, while the highest target is $230, suggesting 54.8% potential gain. The ratings have not changed in the past three months.

PTC India Limited said its 27th AGM will be held Sept 30, 2026 at 12:30 PM via video conferencing. The company set Oct 7, 2026 as the record date for the proposed final dividend for FY 2025-26. The board recommended a 55% final dividend, Rs 5.50 per equity share of Rs 10, according to the company.